Chronix Biomedical

The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.

The move will add Chronix's proprietary technology for blood-based immune therapy monitoring and transplant rejection testing to Oncocyte's existing test menu.